ArticleToxicology and applied pharmacology2025
Comparison of in utero phthalate exposure on fetal rat testis transcript and endocrine alterations with apical reproductive alterations in male rats.
Article in Toxicology and applied pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In utero administration of some diortho phthalate esters (PEs) produces reproductive tract malformations in male and female rat offspring via unknown molecular initiating events. Although the molecular initiating event(s) for these effects are unknown, the PEs consistently alter several key endocrine and gene expression events in the fetal male rat providing a signature of in utero PE exposure. We compared the dose-related alterations of in utero PE exposure on gene expression levels, measured with targeted RT-qPCR custom arrays, and ex vivo testosterone production (T Prod) with the reproductive alterations seen in F1 male rats from three different PE studies. The PEs studied included dicyclohexyl (DCHP) and dipentyl phthalate (DPeP) and a mixture study with five phthalates (DCHP, diethylhexyl (DEHP), dibutyl (DBP), butyl benzyl (BBP), and diisobutyl phthalate (DiBP)). These results demonstrate that targeted testis gene expression and/or T Prod data from short-term prenatal studies conducted during a critical window of fetal masculinization can be used to determine points-of-departure (PODs) for PEs and that these PODs are several fold more protective than the apical effects in postnatal animals. The clear linkage of these gene transcript and testosterone changes to the adverse effects of in utero exposure can facilitate acceptance of the use of gene expression and endocrine data to determine PODs for risk assessment. Furthermore, the use of gene expression and endocrine data from short-term in vivo fetal studies in place of multigenerational reproductive studies for POD determination for PE and mixtures of PEs could increase the rate of POD development for risk assessment and reduce use of animals and other resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.